确保基于寡核酸的产品质量的相关因素
Sara Azari1, Sara Manellari1, Giulia Anderluzzi1
1Department of Pharmaceutical Sciences, University of Milan, Via G. Colombo 71, 20133 Milan, Italy.
International journal of pharmaceutics
|November 23, 2025
概括
寡核酸药物具有显著的治疗潜力,但由于其复杂性,需要专门的临床前评估. 本综述考察了它们的质量属性和监管格局,强调了表征和杀菌方面的挑战.
科学领域:
- 制药科学 制药科学
- 药用化学 医学化学
- 监管科学 监管科学
背景情况:
- 寡核酸是合成化合物,在各种疾病中具有越来越多的治疗应用.
- 它们独特的化学性质需要与小分子相比,不同的临床前评估策略.
- 寡核酸的复杂性给制药开发和监管批准带来了挑战.
研究的目的:
- 审查基于寡核酸的药物的特性和监管框架.
- 确定对寡核酸药物产品的关键质量属性和控制策略.
- 分析来自FDA和EMA等机构的监管授权数据,重点关注质量方面.
主要方法:
- 监管机构 (FDA,EMA) 授权的基于寡核酸的药物的全面审查.
- 质量方面的分析,包括活性物质和药物产品的特征.
- 专注于对寡核酸产品的杂质分析和灭菌方法.
主要成果:
- 奥利冈核酸药物开发面临的复杂性在特征的活性物质和最终的药物产品.
- 杂质分析和杀菌在确保产品质量方面存在重大挑战.
- 现有的监管准则可能需要更新,以充分解决这些复杂性.
结论:
- 了解关键质量属性和实施强有力的控制策略对于寡核酸研发至关重要.
- 监管指南需要不断更新,以支持复杂的寡核酸治疗药物的开发.
- 解决表征和杀菌挑战是推动基于寡核酸的药物的关键.
相关概念视频
02:07Improving Translational Accuracy
14.0K
Base complementarity between the three base pairs of mRNA codon and the tRNA anticodon is not a failsafe mechanism. Inaccuracies can range from a single mismatch to no correct base pairing at all. The free energy difference between the correct and nearly correct base pairs can be as small as 3 kcal/ mol. With complementarity being the only proofreading step, the estimated error frequency would be one wrong amino acid in every 100 amino acids incorporated. However, error frequencies observed in...
14.0K
01:43Proofreading
59.7K
Overview
59.7K
01:31Proofreading
8.6K
Synthesis of new DNA molecules is carried out by the enzyme DNA polymerase, which adds nucleotides on the daughter strand complementary to the template DNA strand. DNA polymerase has a higher affinity to add the correct base and ensures fidelity during DNA replication. Furthermore, it exhibits proofreading activity during replication, using an exonuclease domain that cuts off incorrect nucleotides from the nascent DNA strand.
Errors During Replication are Corrected by the DNA Polymerase...
Errors During Replication are Corrected by the DNA Polymerase...
8.6K